We’ve written a lot about the trend toward pitching genomics and DNA sequencing as the “next big thing” — most of the big newsletter publishers have some kind of spiel out that focuses on the huge growth in genomics, staking out their big winners in this space… and Charles Mizrahi is the latest, with a […]
Articles
I confess, I wanted to write this particular article now because it happens to be partially about a stock I’ve been watching for ages, and that finally hit my “buy” point this week… though yes, the ad for this entry-level Altimetry newsletter is also circulating heavily today, driving a lot of questions my way, even […]
I originally published a teaser solution for this Adam O’Dell pitch on April 12, 2021, and the ad still carries a February 2021 date — but despite that date, the pitch has been modified a bit over the past year, it’s being re-circulated heavily again. This remains one of our most-requested stories, and the ad […]
Yesterday we dug into Luke Lango’s pitch about a synthetic biology stock that he’s calling “the next Microsoft,” but I also promised to cover Lango’s second pitch in that ad… so that’s today’s fuel for the Thinkolator. The urgency of both of these pitches is about the same — the idea is that Lango thinks […]
Dr. David Eifrig has usually one of the more sober pitchmen at Stansberry (odd choice of words for a guy who owns a winery, I guess), and his Retirement Millionaire newsletter (usually sold at $49/yr, renews at $199) is probably his most conservative product — offering up “retirement living” lifestyle advice as well as what […]
This is the latest teaser pitch that a lot of folks have been asking about — and rightly so, I expect, because it’s designed to be extremely topical and get you revved up immediately. Here’s the intro to the ad that I’ve seen in some Angel Publishing newsletters: “We’re now in crisis mode over coronavirus […]
This article originally ran on January 12… the teaser pitch was still being circulated heavily last week, and the stock released earnings on February 3 that disappointed investors, bringing shares down about 15% (it was teased as a “$7 biotech,” and briefly $8, before then). The original Jan. 14 “special event” catalyst teased by Lichtenfeld, […]
[ed note: Dr. KSS is a paid contributor to Stock Gumshoe who writes about biotech stocks for (and discusses them with) the Irregulars. He chooses his own topics, and his words and opinions are his alone. Enjoy!] Greetings fellow Irregulars! You’ve all been waiting for it….our first-ever annual ceremony in which we look back on […]
These are my notes and instant reactions from a presentation at the Value Investing Congress, the notes below might contain errors, paraphrases, incorrect quotes, or misinterpretations. Leon Cooperman is probably known to most of you, he may well be the biggest “CNBC name” at today’s session — he runs Omega Advisors, a $10 billion partnership/hedge […]
Oxidation for Health…Physical and Fiscal[Ed. Note: Dr. KSS writes about medical topics and biotech stocks for the Irregulars. He has agreed to our trading restrictions, and his thoughts and words are his own. Enjoy!] Here we are, solidly in the postmodern 21st century, “so late in the goddam day,” as one of novelist Martin Amis’s characters says, and what […]
We use cookies on this site to enhance your user experience. By clicking any link on this page you are giving your consent for us to set cookies.
More Info
Comments
I am up 12% well since buying it about 8 months ago. I intend to keep this one...
I haven't written about this teaser pitck, but Illumina (ILMN) is one of the largest makers of sequencing machines in th...
Finally worked out for hopeful PACB shareholders... as long as you didn't buy during late 2015 or 2016. I have no idea ...